23:45 , Aug 21, 2018 |  BC Extra  |  Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Luminate: Phase IIb data

The double-blind, U.S. Phase IIb DEL MAR trial in 136 DME patients showed that once-monthly 1 mg Luminate met the primary endpoint of non-inferiority to Avastin bevacizumab in the mean improvement from baseline in BCVA...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Luminate: Completed Phase IIb enrollment

Allegro completed enrollment of 100 patients in the double-blind, placebo-controlled, U.S. Phase IIb PACIFIC trial evaluating 1, 2, 3 and 4 mg intravitreal Luminate given on days 0, 30 and 60. Allegro granted Hanmi a...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Integrin avβ3 (CD51/CD61)

Cancer INDICATION: Cancer In vitro and mouse studies identified a protein inhibitor of the integrin CD51/CD61 that could help treat cancer. In silico analysis of the binding interaction of CD2 analogs with CD51/CD61 and in...
00:42 , Mar 19, 2016 |  BC Extra  |  Company News

Management tracks

Gene editing company CRISPR Therapeutics AG (Basel, Switzerland) named Marc Becker CFO. He was CFO and SVP at rEVO Biologics Inc. (Framingham, Mass.). CRISPR also named Tony Coles, the chairman and CEO of Yumanity Therapeutics...
08:00 , Feb 8, 2016 |  BioCentury  |  Strategy

Worldwide web

Korean biotech Hanmi Pharmaceutical Co. Ltd. is on a mission to globalize. And with six out-licensing deals announced last year, the company appears to be reaping the rewards of its investment in both new technology...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Luminate: Completed Phase IIb enrollment

Allegro completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase IIb DEL MAR trial comparing 1, 2 and 3 mg intravitreal Luminate vs. Avastin bevacizumab. Patients will receive Luminate or Avastin at day...
01:49 , Oct 24, 2015 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Unum Therapeutics Inc. (Cambridge, Mass.) named Michael Vasconcelles CMO. Vasconcelles was SVP and global head of the oncology therapy area unit at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Ophthalmology company Allegro Ophthalmics LLC (San...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Luminate: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 106 patients with VMT or VMA showed that 3.2 mg intravitreal Luminate met the primary endpoint of a greater proportion of patients achieving release of...
01:25 , Jul 14, 2015 |  BC Extra  |  Clinical News

Allegro reports Phase II Luminate data in vitreoretinal disease

Allegro Ophthalmics LLC (San Juan Capistrano, Calif.) said the highest of three Luminate ( ALG-1001 ) doses met the primary endpoint in a Phase II trial to treat vitreomacular traction (VMT) or vitreomacular adhesion (VMA)....